These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 17049683)

  • 21. Alloimmunity does not protect from challenge with the feline immunodeficiency virus.
    Reggeti F; Bienzle D
    Vet Immunol Immunopathol; 2008 Jul; 124(1-2):152-62. PubMed ID: 18471896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.
    Hosie MJ; Dunsford T; Klein D; Willett BJ; Cannon C; Osborne R; Macdonald J; Spibey N; Mackay N; Jarrett O; Neil JC
    J Virol; 2000 Oct; 74(20):9403-11. PubMed ID: 11000209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vaccination of cats against infection with feline leukemia virus (FeLV): first recombinant vaccine and the effect of a pre-existing infection with feline immunodeficiency virus (FIV)].
    Hofmann-Lehmann R; Aubert A; Wolfensberger C; Cronier J; Lutz H
    Schweiz Arch Tierheilkd; 1994; 136(10):340-51. PubMed ID: 7801087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term immunity in cats vaccinated with an inactivated trivalent vaccine.
    Scott FW; Geissinger CM
    Am J Vet Res; 1999 May; 60(5):652-8. PubMed ID: 10328440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus.
    Matteucci D; Pistello M; Mazzetti P; Giannecchini S; Isola P; Merico A; Zaccaro L; Rizzuti A; Bendinelli M
    Vaccine; 1999 Aug; 18(1-2):119-30. PubMed ID: 10501242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New challenges for the diagnosis of feline immunodeficiency virus infection.
    Crawford PC; Levy JK
    Vet Clin North Am Small Anim Pract; 2007 Mar; 37(2):335-50, vii. PubMed ID: 17336678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
    Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
    Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A DNA vaccine expressing the E2 protein of classical swine fever virus elicits T cell responses that can prime for rapid antibody production and confer total protection upon viral challenge.
    Ganges L; Barrera M; Núñez JI; Blanco I; Frias MT; Rodríguez F; Sobrino F
    Vaccine; 2005 May; 23(28):3741-52. PubMed ID: 15882536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The development of a vaccine against feline immunodeficiency virus.
    Hosie MJ
    Br Vet J; 1994; 150(1):25-39. PubMed ID: 8025833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of feline immunodeficiency virus ORF-A mutants as candidate attenuated vaccine.
    Pistello M; Bonci F; Isola P; Mazzetti P; Merico A; Zaccaro L; Matteucci D; Bendinelli M
    Virology; 2005 Feb; 332(2):676-90. PubMed ID: 15680433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should accessory proteins be structural components of lentiviral vaccines? Lessons learned from the accessory ORF-A protein of FIV.
    Pistello M
    Vet Immunol Immunopathol; 2008 May; 123(1-2):144-9. PubMed ID: 18304653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.
    Hofmann-Lehmann R; Holznagel E; Aubert A; Ossent P; Reinacher M; Lutz H
    Vet Immunol Immunopathol; 1995 May; 46(1-2):127-37. PubMed ID: 7618252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward vaccination against feline leukemia virus and feline immunodeficiency virus infections.
    Osterhaus AD; Weijer K; Siebelink KH; Rimmelzwaan GF; Bosch ML
    J Am Vet Med Assoc; 1991 Nov; 199(10):1443-6. PubMed ID: 1666100
    [No Abstract]   [Full Text] [Related]  

  • 35. Early suppression of viremia by ZDV does not alter the spread of feline immunodeficiency virus infection in cats.
    Hayes KA; Wilkinson JG; Frick R; Francke S; Mathes LE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):114-22. PubMed ID: 7749786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approaches to vaccination against the feline immunodeficiency virus.
    Pistello M; Conti F; Vannucci L; Freer G
    Vet Immunol Immunopathol; 2010 Mar; 134(1-2):48-53. PubMed ID: 19896725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine.
    Omori M; Pu R; Tanabe T; Hou W; Coleman JK; Arai M; Yamamoto JK
    Vaccine; 2004 Dec; 23(3):386-98. PubMed ID: 15530685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
    Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
    AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT.
    Dean GA; LaVoy A; Burkhard MJ
    Vet Immunol Immunopathol; 2004 Jul; 100(1-2):49-59. PubMed ID: 15182995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.